0

A Phellinus Baumii Extract Reduces Obesity in High-Fat Diet-Fed Mice and Absorption of Triglyceride in Lipid-Loaded Mice

Jung-Ran Noh, In-Kyoung Lee, Sun-Yung Ly, Keum-Jin Yang, Gil-Tae Gang, Yong-Hoon Kim, Jung-Hwan Hwang, Bong-Sik Yun, Chul-Ho Lee

J Med Food. 2011 Mar;14(3):209-18.

PMID: 21332399

Abstract:

This study evaluated the anti-obesity effects of Phellinus baumii extract (PBE) in high-fat diet (HFD)-fed mice. Male 8-week-old C57BL/6 mice were randomly divided into four groups: control, normal chow diet plus vehicle; HFD-control, high-fat plus vehicle; HFD plus orlistat (Xenical(®), Roche, Basel, Switzerland) (50 mg/kg); and HFD plus PBE (500 mg/kg). PBE was administered daily by oral gavage for 12 weeks. Oral administration of PBE (500 mg/kg) significantly reduced body weight gain, hepatic lipid concentrations, and fat accumulation in epididymal adipocytes compared with mice fed HFD alone (P < .05). mRNA expression of genes related to triglyceride (TG) synthesis was suppressed in the PBE groups, and fatty acid synthase activity was also significantly inhibited (P < .05). Furthermore, we evaluated the effect of PBE on TG absorption and detected marked reduction in TG absorption in Xenical- and PBE-treated mice compared with the control group (P < .05). To determine the active compound of PBE, fractionation was conducted, and interfungin A, davallialactone, and hypholomine B were identified as the main compounds. Among the three identified compounds, as a representative compound, davallialactone was also shown to suppress fat accumulation in an in vitro model system. These anti-obesity and hypolipidemic effects appear to be partly mediated by suppressing plasma and hepatic fat accumulation through the inhibition of enzymes associated with hepatic and intestinal lipid absorption and synthesis.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
AP19740728 Orlistat Related Compound B Orlistat Related Compound B 19740-72-8 Price
qrcode